FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change

por Nathan, Steven D., Yang, Ming, Morgenthien, Elizabeth A., Stauffer, John L.
Publicado 2020

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management

por van Cleemput, Johan, Sonaglioni, Andrea, Wuyts, Wim A., Bengus, Monica, Stauffer, John L., Harari, Sergio
Publicado 2018

Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis

por LaCamera, Peter P, Limb, Susan L, Haselkorn, Tmirah, Morgenthien, Elizabeth A, Stauffer, John L, Wencel, Mark L
Publicado 2019

Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

por Wencel, Mark L., Haselkorn, Tmirah, Limb, Susan L., Stauffer, John L., Morgenthien, Elizabeth, Raimundo, Karina, LaCamera, Peter P.
Publicado 2018

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

por Glassberg, Marilyn K., Nathan, Steven D., Lin, Chin-Yu, Morgenthien, Elizabeth A., Stauffer, John L., Chou, Willis, Noble, Paul W.
Publicado 2019

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

por Glassberg, Marilyn K., Nathan, Steven D., Lin, Chin-Yu, Morgenthien, Elizabeth A., Stauffer, John L., Chou, Willis, Noble, Paul W.
Publicado 2019

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)

por Gotfried, Mark H., Girod, Carlos E., Antin-Ozerkis, Danielle, Burgess, Tracy, Strombom, Indiana, Stauffer, John L., Kirchgaessler, Klaus-Uwe, Padilla, Maria L.
Publicado 2018

Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonar...

por Holtze, Colin H., Freiheit, Elizabeth A., Limb, Susan L., Stauffer, John L., Raimundo, Karina, Pan, Wayne T., Flaherty, Kevin R., Kim, Hyun J.
Publicado 2020

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis

por Flaherty, Kevin R., Fell, Charlene D., Huggins, J. Terrill, Nunes, Hilario, Sussman, Robert, Valenzuela, Claudia, Petzinger, Ute, Stauffer, John L., Gilberg, Frank, Bengus, Monica, Wijsenbeek, Marlies
Publicado 2018

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

por Cottin, Vincent, Koschel, Dirk, Günther, Andreas, Albera, Carlo, Azuma, Arata, Sköld, C. Magnus, Tomassetti, Sara, Hormel, Philip, Stauffer, John L., Strombom, Indiana, Kirchgaessler, Klaus-Uwe, Maher, Toby M.
Publicado 2018

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis

por Lancaster, Lisa H., de Andrade, Joao A., Zibrak, Joseph D., Padilla, Maria L., Albera, Carlo, Nathan, Steven D., Wijsenbeek, Marlies S., Stauffer, John L., Kirchgaessler, Klaus-Uwe, Costabel, Ulrich
Publicado 2017